GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » StageZero Life Sciences Ltd (TSX:SZLS) » Definitions » YoY EPS Growth

StageZero Life Sciences (TSX:SZLS) YoY EPS Growth : -1,300.00% (As of Sep. 2023)


View and export this data going back to 2001. Start your Free Trial

What is StageZero Life Sciences YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. StageZero Life Sciences's YoY EPS Growth for the quarter that ended in Sep. 2023 was -1,300.00%.

StageZero Life Sciences's Earnings per Share (Diluted) for the three months ended in Sep. 2023 was C$-0.01.


StageZero Life Sciences YoY EPS Growth Historical Data

The historical data trend for StageZero Life Sciences's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

StageZero Life Sciences YoY EPS Growth Chart

StageZero Life Sciences Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.74 1.86 9.00 26.56 -5.67

StageZero Life Sciences Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 96.00 -90.63 -107.69 69.23 -1,300.00

StageZero Life Sciences YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

StageZero Life Sciences's YoY EPS Growth for the fiscal year that ended in Dec. 2022 is calculated as:

YoY EPS Growth (A: Dec. 2022 )
=(Earnings per Share (Diluted) (A: Dec. 2022 )-Earnings per Share (Diluted) (A: Dec. 2021 ))/ | Earnings per Share (Diluted) (A: Dec. 2021 ) |
=(-0.149--0.141)/ | -0.141 |
=-5.67 %

StageZero Life Sciences's YoY EPS Growth for the quarter that ended in Sep. 2023 is calculated as:

YoY EPS Growth (Q: Sep. 2023 )
=(Earnings per Share (Diluted) (Q: Sep. 2023 )-Earnings per Share (Diluted) (Q: Sep. 2022 )) / | Earnings per Share (Diluted) (Q: Sep. 2022 )) |
=(-0.014--0.001)/ | -0.001 |
=-1,300.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


StageZero Life Sciences YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of StageZero Life Sciences's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.


StageZero Life Sciences (TSX:SZLS) Business Description

Traded in Other Exchanges
Address
70 East Beaver Creek Road, Unit 30, Richmond Hill, ON, CAN, L4B 3B2
StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.

StageZero Life Sciences (TSX:SZLS) Headlines

No Headlines